Prot #CYTB323I12201: A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants with Severe Active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiiti

Project: Research project

Project Details

StatusActive
Effective start/end date10/15/24 → 12/29/29

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CYTB323I12201)